PMA · Approved
ApprovedTRUFILL n-Butyl Cyanoacrylate (n-BCA) Liquid Embolic System
Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly
Cerenovus, Inc. · KGG Tissue Adhesive For Use In Embolization Of Brain Arteriovenous Malformations
Approved on Jul 2, 2024 through premarket approval, which rests on the device’s own clinical evidence after an 88-day review.
- Decided
- Jul 2, 2024
- Review
- 88 days
- Class
- Class III
- Product code
- KGG
- Recalls
- None
PMA approvals rest on their own clinical evidence and do not claim a predicate, so this family tree starts here.
Sources: FDA PMA database (decision fields and supplements), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.
Planning a device in KGG? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.
- Candidate predicates for a device like this, rankedin the report
- Recall history across each candidate’s familyin the report
Does it have a predicate?
PMA decisions do not claim a predicate device.
What descends from it?
No later submission names this one as a predicate yet.
Has anything in its family been recalled? (0 Class I)
No FDA recall names this device.
No ancestor or descendant has a Class I recall.
How does its category compare?
All KGG devicesKGG Tissue Adhesive For Use In Embolization Of Brain Arteriovenous Malformations: FDA decisions, review times, recalls and adverse event reports over 20 years. 2024, this device’s year, is highlighted.
FDA decisions per year · KGG
2in 2025
2026 to Oct 25, outlined.
Median 510(k) review, days · KGG
Too few KGG 510(k)s in any year since 2007 to give a median.
Recalls per year · KGG
2in 2013
Class I (2 since 2007) Class II/III not classified
Adverse event reports per year · KGG
16in 2025
MAUDE reports naming product code KGG, not matched to any one device; reports are not rates.
View these four charts as a table
| Year | Decisions | Median 510(k) review, days | Recalls (Class I) | MAUDE reports |
|---|---|---|---|---|
| 2007 | 2 | — | 0 | 0 |
| 2008 | 0 | — | 0 | 1 |
| 2009 | 3 | — | 0 | 0 |
| 2010 | 6 | — | 0 | 0 |
| 2011 | 1 | — | 0 | 1 |
| 2012 | 0 | — | 0 | 9 |
| 2013 | 1 | — | 2 (2) | 3 |
| 2014 | 1 | — | 0 | 0 |
| 2015 | 2 | — | 0 | 0 |
| 2016 | 2 | — | 0 | 3 |
| 2017 | 2 | — | 0 | 10 |
| 2018 | 2 | — | 0 | 0 |
| 2019 | 2 | — | 0 | 7 |
| 2020 | 0 | — | 0 | 12 |
| 2021 | 0 | — | 0 | 10 |
| 2022 | 0 | — | 0 | 5 |
| 2023 | 2 | — | 0 | 7 |
| 2024 | 2 | — | 0 | 6 |
| 2025 | 2 | — | 0 | 16 |
| 2026 | 2 | — | 0 | — |
https://510kreport.com/device/P990040/S033 · printed Nov 6, 2026
Cite this page
510(k) Report. “P990040/S033: TRUFILL n-Butyl Cyanoacrylate (n-BCA) Liquid Embolic System.” Lineage record from FDA PMA data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/P990040/S033
Report an extraction error
Are you the manufacturer?
Record history
- FDA decision record loaded May 2, 2026
- Page last updated Nov 3, 2026